GILDCongressional Stock Trades
Gilead Sciences Inc
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Gilead Sciences Inc (GILD) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
17
Politicians Trading
9
Last Traded
Aug 10, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| John BoozmanR | May 14, 2025 | Apr 16, 2025 | Sell | $1,001 - $15,000 | +59.68% |
Price History
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
9 members of Congress have disclosed 17 trades in Gilead Sciences Inc (GILD). Most active: Josh Gottheimer (3), Marjorie Taylor Greene (3), Ro Khanna (3).
Across all disclosures, members of Congress reported 11 purchases and 6 sales of Gilead Sciences Inc (GILD). The most recent trade was on Aug 10, 2026.
Ro Khanna disclosed buying Gilead Sciences Inc (GILD) on Jul 20, 2026, valued at $1,001 - $15,000.
Ro Khanna disclosed selling Gilead Sciences Inc (GILD) on Aug 10, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.